Tighter watch urged on adenoviral vectors...with proposal to report all 'adverse events'.
Smaglik
P
P
D000256:Adenoviridae / Q000235:genetics*; D000328:Adult; D026683:Advisory Committees; D000641:Ammonia / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence / Q000592:standards; D015316:Genetic Therapy / Q000009:adverse effects* / Q000331:legislation & jurisprudence / Q000592:standards; D005822:Genetic Vectors / Q000009:adverse effects*; D033161:Government Regulation; D006801:Humans; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D008297:Male; D009316:National Institutes of Health (U.S.); D009954:Ornithine Carbamoyltransferase / Q000235:genetics; D035842:Research Subjects; D014342:Truth Disclosure; D014481:United States; D014486:United States Food and Drug Administration
D000641:Ammonia; D009954:Ornithine Carbamoyltransferase